AR-GLP1 mimics the action of endogenous GLP1 and effectively reduces HbA1c without the risk of hypoglycemia by increasing insulin secretion in a glucose-dependent manner and decreasing glucagon secretion. In addition, they produce weight loss and provide a greater feeling of satiety.

Among them are Dulaglutide, Exenatide, Semaglutide, Liraglutide, Lixisenatide, Semaglutide, and others.

The researchers from Case Western Reserve University in the United States suggest that this class of drugs used to treat type 2 diabetes may also reduce the risk of CRC.

“Our results clearly demonstrate that GLP-1 RAs are significantly more effective than the better-known antidiabetic drugs, such as metformin or insulin, in preventing the onset of CRC,” the scientists stressed, cited in the journal JAMA Oncology.

These, they noted, could prove promising for preventing other types of cancer associated with obesity and diabetes.

The protective effect of GLP-1 RAs is observed in both overweight and non-overweight patients, the experts emphasize.

jrr/jav/mem/joe